Elham Ahmadi's research works | McMaster University, Hamilton (McMaster) and other places

What is this page?

This page lists the scientific contributions of an author, who either does not have a ResearchGate profile, or has not yet added these contributions to their profile.

It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.

If you're a ResearchGate member, you can follow this page to keep up with this author's work.

If you are this author, and you don't want us to display this page anymore, please let us know.

Fig. 1. Representative baseline PSMA-PET, metastasis-directed RT (MDRT)...

Fig. 2. SMA expression in human prostate tumor specimens. PSMA...

Fig. 4. PSMA expression in untreated and irradiated prostate cancer...

Fig. 5. PSMA expression in radiation-resistant clones of prostate...

18F-DCFPyL (PSMA) PET as a radiotherapy response assessment tool in metastatic prostate cancer

Article

Full-text available

Mar 2023

Background: Prostate Specific Membrane Antigen (PSMA) - positron emission tomography (PET) guides metastasis-directed radiotherapy (MDRT) in prostate cancer (PrCa). However, its value as a treatment response assessment tool after MDRT remains unclear. Importantly, there is limited understanding of the potential of radiotherapy (RT) to alter PSMA g...

Inhibition of ATP-citrate lyase improves NASH, liver fibrosis, and dyslipidemia

Article

Jun 2022

Elevated liver de novo lipogenesis contributes to non-alcoholic steatohepatitis (NASH) and can be inhibited by targeting acetyl-CoA carboxylase (ACC). However, hypertriglyceridemia limits the use of pharmacological ACC inhibitors as a monotherapy. ATP-citrate lyase (ACLY) generates acetyl-CoA and oxaloacetate from citrate, but whether inhibition is...

Fig. 1. Response of PrCa cells to Metformin (MET) and radiotherapy...

Combined metformin-salicylate treatment provides improved anti-tumor activity and enhanced radiotherapy response in prostate cancer; drug synergy at clinically relevant doses

Article

Full-text available

Nov 2021

Background There is need for well-tolerated therapies for prostate cancer (PrCa) secondary prevention and to improve response to radiotherapy (RT). The anti-diabetic agent metformin (MET) and the aspirin metabolite salicylate (SAL) are shown to activate AMP-activated protein kinase (AMPK), suppress de novo lipogenesis (DNL), the mammalian target of...